Corilagin

Corilagin

SCHEMBL329080

O=C(O[C@@H]1O[C@@H]2COC(=O)c3cc(O)c(O)c(O)c3-c3c(cc(O)c(O)c3O)C(=O)O[C@H]([C@H]1O)[C@@H]2O)c1cc(O)c(O)c(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 8/20 1.00
PRKCG P05129 8/20 1.00
PRKCB P05771 8/20 1.00
PRKCA P17252 8/20 1.00
PRKCH P24723 8/20 1.00
PRKCI P41743 8/20 1.00
PRKCE Q02156 8/20 1.00
PRKCQ Q04759 8/20 1.00
PRKCZ Q05513 8/20 1.00
PRKCD Q05655 8/20 1.00
PRKD1 Q15139 8/20 1.00
RAD52 P43351 2/20 1.00
USP2 O75604 1/20 1.00
LMNA P02545 1/20 1.00
POLB P06746 1/20 1.00
GAA P10253 1/20 1.00
MAPT P10636 1/20 1.00
HPGD P15428 1/20 1.00
TNNI3 P19429 1/20 1.00
APEX1 P27695 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Corilagin SCHEMBL21026424 1.00 PRKD3 (1.00) PRKD3PRKCGPRKCBPRKCAPRKCH
Corilagin SCHEMBL14075996 1.00 PRKD3 (1.00) PRKD3PRKCGPRKCBPRKCAPRKCH
Corilagin SCHEMBL30208566 1.00 PRKD3 (1.00) PRKD3PRKCGPRKCBPRKCAPRKCH
Corilagin SCHEMBL29994662 1.00 PRKD3 (1.00) PRKD3PRKCGPRKCBPRKCAPRKCH
Corilagin SCHEMBL14089650 1.00 PRKD3 (1.00) PRKD3PRKCGPRKCBPRKCAPRKCH
Corilagin SCHEMBL18415304 1.00 PRKD3 (1.00) PRKD3PRKCGPRKCBPRKCAPRKCH
Corilagin SCHEMBL13242674 1.00 PRKD3 (1.00) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL20409294 0.93 PRKD3 (0.88) PRKD3PRKCGPRKCBPRKCAPRKCH
Strictinin SCHEMBL15262426 0.92 RAD52 (1.00) PRKD3PRKCGPRKCBPRKCAPRKCH
Strictinin SCHEMBL17148972 0.92 RAD52 (1.00) PRKD3PRKCGPRKCBPRKCAPRKCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122074627-A Preparation method of low-GI fruit and vegetable crisp chips 2026-05-26 CN claimed
CN-122012665-A Three-fruit Shang Kangyan component high-screening method based on intestinal flora metabolic model 青岛科技大学 2026-05-12 CN claimed
CN-117741031-B Construction method, detection method and application of strong Ma De Tu Alite preparation fingerprint 新疆维吾尔药业有限责任公司 2026-05-12 CN claimed
US-20260084136-A1 SUPERABSORBENT POLYMER, METHOD OF MAKING THE SAME, AND A FOODSTUFF PACKAGING MATERIAL INCLUDING THE SAME FORMOSA PLASTICS CORP (TW) 2026-03-26 US claimed
EP-4715000-A1 SUPERABSORBENT POLYMER, METHOD OF MAKING THE SAME, AND A FOODSTUFF PACKAGING MATERIAL INCLUDING THE SAME Formosa Plastics Corporation (TW) 2026-03-25 EP claimed
WO-2025264604-A1 SKIN CARE COMPOSITION AND METHOD OF USING THE SAME THE PROCTER & GAMBLE COMPANY (US) 2025-12-26 WO claimed
US-20250381110-A1 SKIN CARE COMPOSITION AND METHOD OF USING THE SAME PROCTER & GAMBLE (US) 2025-12-18 US claimed
EP-4615506-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES Sahin, Fikret (TR) 2025-09-17 EP claimed
EP-4611549-A1 COMPOSTABLE CAPSULE AND PRODUCTION THEREOF Delica AG (CH) 2025-09-10 EP claimed
CN-120114873-A Preparation method and application of phyllanthus emblica juice polyphenol extract 广东药科大学 2025-06-10 CN claimed
WO-2002028403-A1 PHYLLANTHUS-DERIVED COMPOUNDS FOR THE PREVENTION AND/OR TREATMENT OF DISEASES ASSOCIATED WITH A RETROVIRUS CMI - CENTERS FOR MEDICAL INNOVATION AG (DE) 2002-04-11 WO claimed
CN-1319411-A Traditional Chinese medicine compound preparation for treating chronic hepatitis B and preparation process thereof HOSPITAL AFFILIATED TO HUBEI T (CN) 2001-10-31 CN claimed
EP-1144456-A2 METHOD OF ISOLATING MUCILAGINOUS POLYSACCHARIDES AND USES THEREOF Vito-Mannan Polysaccharide L.L.C. (US) 2001-10-17 EP claimed
WO-2000056347-A1 AN ENRICHED FRACTION PREPARED FROM PHYLLANTHUS AMARUS FOR THE TREATMENT OF HEPATITIS AND THE PREPARATION THEREOF SOUTHERN PETROCHEMICAL INDUSTRIES CORPORATION LIMITED (IN) 2000-09-28 WO claimed
WO-2000041541-A2 METHOD OF ISOLATING MUCILAGINOUS POLYSACCHARIDES AND USES THEREOF VITO-MANNAN POLYSACCHARIDE L.L.C. (US) 2000-07-20 WO claimed
WO-2000027413-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HEPATITIS B COMPRISING CORILAGIN OR BREVIFOLIN CARBOXYLIC ACID HEPAGUARD CO., LTD. (KR) 2000-05-18 WO claimed
CN-1197641-A Medicine containing tan matter caesalpinia extract SINO JAPAN FRIENDSHIP INST OF (CN) 1998-11-04 CN claimed
US-5266319-A Tannin derivatives and their use for treatment of hypertension NATIONAL SCIENCE COUNCIL (TW) 1993-11-30 US claimed
US-5173117-A Hydrolyzable tannin compound, controls heat of hydration SUMITOMO CEMENT CO. LTD. (JP) 1992-12-22 US claimed
WO-1990004968-A1 INHIBITION OF HUMAN RETROVIRUSES UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1990-05-17 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260084136-A1 SUPERABSORBENT POLYMER, METHOD OF MAKING THE SAME, AND A FOODSTUFF PACKAGING MATERIAL INCLUDING THE SAME TAS2R40, SI, FTO PRKD3 3844/4885PRKCG 4489/4885PRKCB 4506/4885
US-20250381110-A1 SKIN CARE COMPOSITION AND METHOD OF USING THE SAME SQSTM1, BECN1, CUTA PRKD3 1064/4885PRKCG 364/4885PRKCB 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.